Biopharmaceuticals-United States Market Status and Trend Report 2013-2023
SKU ID :MI-11647010 | Published Date: 21-May-2018 | No. of pages: 132Description
TOC
Table of Contents
Chapter 1 Overview of Biopharmaceuticals
1.1 Definition of Biopharmaceuticals in This Report
1.2 Commercial Types of Biopharmaceuticals
1.2.1 Monoclonal Antibodies
1.2.2 Interferon
1.2.3 Colony-Stimulating Factor
1.2.4 Erythropoietin
1.2.5 Insulin
1.2.6 Vaccines
1.2.7 Growth Hormones
1.2.8 Other
1.3 Downstream Application of Biopharmaceuticals
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biopharmaceuticals
1.5 Market Status and Trend of Biopharmaceuticals 2013-2023
1.5.1 United States Biopharmaceuticals Market Status and Trend 2013-2023
1.5.2 Regional Biopharmaceuticals Market Status and Trend 2013-2023
Chapter 2 United States Market Status and Forecast by Regions
2.1 Market Status of Biopharmaceuticals in United States 2013-2017
2.2 Consumption Market of Biopharmaceuticals in United States by Regions
2.2.1 Consumption Volume of Biopharmaceuticals in United States by Regions
2.2.2 Revenue of Biopharmaceuticals in United States by Regions
2.3 Market Analysis of Biopharmaceuticals in United States by Regions
2.3.1 Market Analysis of Biopharmaceuticals in New England 2013-2017
2.3.2 Market Analysis of Biopharmaceuticals in The Middle Atlantic 2013-2017
2.3.3 Market Analysis of Biopharmaceuticals in The Midwest 2013-2017
2.3.4 Market Analysis of Biopharmaceuticals in The West 2013-2017
2.3.5 Market Analysis of Biopharmaceuticals in The South 2013-2017
2.3.6 Market Analysis of Biopharmaceuticals in Southwest 2013-2017
2.4 Market Development Forecast of Biopharmaceuticals in United States 2018-2023
2.4.1 Market Development Forecast of Biopharmaceuticals in United States 2018-2023
2.4.2 Market Development Forecast of Biopharmaceuticals by Regions 2018-2023
Chapter 3 United States Market Status and Forecast by Types
3.1 Whole United States Market Status by Types
3.1.1 Consumption Volume of Biopharmaceuticals in United States by Types
3.1.2 Revenue of Biopharmaceuticals in United States by Types
3.2 United States Market Status by Types in Major Countries
3.2.1 Market Status by Types in New England
3.2.2 Market Status by Types in The Middle Atlantic
3.2.3 Market Status by Types in The Midwest
3.2.4 Market Status by Types in The West
3.2.5 Market Status by Types in The South
3.2.6 Market Status by Types in Southwest
3.3 Market Forecast of Biopharmaceuticals in United States by Types
Chapter 4 United States Market Status and Forecast by Downstream Industry
4.1 Demand Volume of Biopharmaceuticals in United States by Downstream Industry
4.2 Demand Volume of Biopharmaceuticals by Downstream Industry in Major Countries
4.2.1 Demand Volume of Biopharmaceuticals by Downstream Industry in New England
4.2.2 Demand Volume of Biopharmaceuticals by Downstream Industry in The Middle Atlantic
4.2.3 Demand Volume of Biopharmaceuticals by Downstream Industry in The Midwest
4.2.4 Demand Volume of Biopharmaceuticals by Downstream Industry in The West
4.2.5 Demand Volume of Biopharmaceuticals by Downstream Industry in The South
4.2.6 Demand Volume of Biopharmaceuticals by Downstream Industry in Southwest
4.3 Market Forecast of Biopharmaceuticals in United States by Downstream Industry
Chapter 5 Market Driving Factor Analysis of Biopharmaceuticals
5.1 United States Economy Situation and Trend Overview
5.2 Biopharmaceuticals Downstream Industry Situation and Trend Overview
Chapter 6 Biopharmaceuticals Market Competition Status by Major Players in United States
6.1 Sales Volume of Biopharmaceuticals in United States by Major Players
6.2 Revenue of Biopharmaceuticals in United States by Major Players
6.3 Basic Information of Biopharmaceuticals by Major Players
6.3.1 Headquarters Location and Established Time of Biopharmaceuticals Major Players
6.3.2 Employees and Revenue Level of Biopharmaceuticals Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
Chapter 7 Biopharmaceuticals Major Manufacturers Introduction and Market Data
7.1 Roche
7.1.1 Company profile
7.1.2 Representative Biopharmaceuticals Product
7.1.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Roche
7.2 Amgen
7.2.1 Company profile
7.2.2 Representative Biopharmaceuticals Product
7.2.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Amgen
7.3 AbbVie
7.3.1 Company profile
7.3.2 Representative Biopharmaceuticals Product
7.3.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of AbbVie
7.4 Sanofi-Aventis
7.4.1 Company profile
7.4.2 Representative Biopharmaceuticals Product
7.4.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
7.5 Johnson & Johnson
7.5.1 Company profile
7.5.2 Representative Biopharmaceuticals Product
7.5.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.6 Pfizer
7.6.1 Company profile
7.6.2 Representative Biopharmaceuticals Product
7.6.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Pfizer
7.7 Novo Nordisk
7.7.1 Company profile
7.7.2 Representative Biopharmaceuticals Product
7.7.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novo Nordisk
7.8 Eli Lilly
7.8.1 Company profile
7.8.2 Representative Biopharmaceuticals Product
7.8.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Eli Lilly
7.9 Novartis
7.9.1 Company profile
7.9.2 Representative Biopharmaceuticals Product
7.9.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novartis
7.10 Merck
7.10.1 Company profile
7.10.2 Representative Biopharmaceuticals Product
7.10.3 Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Merck
Chapter 8 Upstream and Downstream Market Analysis of Biopharmaceuticals
8.1 Industry Chain of Biopharmaceuticals
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
Chapter 9 Cost and Gross Margin Analysis of Biopharmaceuticals
9.1 Cost Structure Analysis of Biopharmaceuticals
9.2 Raw Materials Cost Analysis of Biopharmaceuticals
9.3 Labor Cost Analysis of Biopharmaceuticals
9.4 Manufacturing Expenses Analysis of Biopharmaceuticals
Chapter 10 Marketing Status Analysis of Biopharmaceuticals
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
Chapter 11 Report Conclusion
Chapter 12 Research Methodology and Reference
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
Tables & Figures
List of Tables
Table Advantage and Disadvantage of Monoclonal Antibodies
Table Advantage and Disadvantage of Interferon
Table Advantage and Disadvantage of Colony-Stimulating Factor
Table Advantage and Disadvantage of Erythropoietin
Table Advantage and Disadvantage of Insulin
Table Advantage and Disadvantage of Vaccines
Table Advantage and Disadvantage of Growth Hormones
Table Advantage and Disadvantage of Other
Table Consumption Volume of Biopharmaceuticals in United States by Regions 2013-2017
Table Revenue of Biopharmaceuticals in United States by Regions 2013-2017
Table Consumption Volume of Biopharmaceuticals in United States by Regions 2018-2023
Table Revenue of Biopharmaceuticals in United States by Regions 2018-2023
Table Consumption Volume of Biopharmaceuticals in United States by Types 2013-2017
Table Revenue of Biopharmaceuticals in United States by Types 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in New England 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in The Middle Atlantic 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in The Midwest 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in The West 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in The South 2013-2017
Table Consumption Volume of Biopharmaceuticals by Types in Southwest 2013-2017
Table Consumption Volume Forecast of Biopharmaceuticals in United States by Types 2018-2023
Table Revenue Forecast of Biopharmaceuticals in United States by Types 2018-2023
Table Demand Volume of Biopharmaceuticals in United States by Downstream Industry 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in New England 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in The Middle Atlantic 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in The Midwest 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in The West 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in The South 2013-2017
Table Demand Volume of Biopharmaceuticals by Downstream Industry in Southwest 2013-2017
Table Demand Volume Forecast of Biopharmaceuticals in United States by Downstream Industry 2018-2023
Table Sales Volume of Biopharmaceuticals in United States by Major Players 2013-2017
Table Revenue of Biopharmaceuticals in United States by Major Players 2013-2017
Table Headquarters Location and Established Time of Biopharmaceuticals Major Players
Table Employees and Revenue Level of Biopharmaceuticals Major Players
Table Representative Biopharmaceuticals Product One of Roche
Table Representative Biopharmaceuticals Product Two of Roche
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Roche 2013-2017
Table Representative Biopharmaceuticals Product One of Amgen
Table Representative Biopharmaceuticals Product Two of Amgen
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Amgen 2013-2017
Table Representative Biopharmaceuticals Product One of AbbVie
Table Representative Biopharmaceuticals Product Two of AbbVie
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of AbbVie 2013-2017
Table Representative Biopharmaceuticals Product One of Sanofi-Aventis
Table Representative Biopharmaceuticals Product Two of Sanofi-Aventis
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Sanofi-Aventis 2013-2017
Table Representative Biopharmaceuticals Product One of Johnson & Johnson
Table Representative Biopharmaceuticals Product Two of Johnson & Johnson
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Johnson & Johnson 2013-2017
Table Representative Biopharmaceuticals Product One of Pfizer
Table Representative Biopharmaceuticals Product Two of Pfizer
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Pfizer 2013-2017
Table Representative Biopharmaceuticals Product One of Novo Nordisk
Table Representative Biopharmaceuticals Product Two of Novo Nordisk
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novo Nordisk 2013-2017
Table Representative Biopharmaceuticals Product One of Eli Lilly
Table Representative Biopharmaceuticals Product Two of Eli Lilly
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Eli Lilly 2013-2017
Table Representative Biopharmaceuticals Product One of Novartis
Table Representative Biopharmaceuticals Product Two of Novartis
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Novartis 2013-2017
Table Representative Biopharmaceuticals Product One of Merck
Table Representative Biopharmaceuticals Product Two of Merck
Table Biopharmaceuticals Sales, Revenue, Price and Gross Margin of Merck 2013-2017
Companies
- PRICE
-
$3480$5980